GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion diagnostic prod ...

Burning Rock Biotech Limited (NASDAQ:BNR) Q1 2023 Earnings Conference Call May 29, 2024 8:00 AM ET Company Participants Yusheng Han - Founder and Chief Executive Officer Leo Li - Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to the Burning Rock’s 2024 First Quarter Earnings Conference Call. At this time all participants are in listen-only mode. Please be advised that this conference is being recorded. Before we begin, I'd like to remind you tha ...

Financial Performance & Efficiency - Burning Rock's Q1 2024 revenues reached RMB 125.6 million, a 4% increase QoQ, but a 12% decrease YoY[33] - Non-GAAP gross profit for Q1 2024 was RMB 93.0 million, a 7% increase QoQ, but a 14% decrease YoY[33] - The company is driving sales efficiency, expecting selling expenses to be below 40% going forward[20] - Non-GAAP general and administrative expenses decreased from RMB 51 million in Q1 2023 to RMB 38 million in Q1 2024, a 26% decrease[30,31] - The company's commercial operation (excluding R&D expenses) reached profitability in Q1 2024[32] MRD & Early Detection Technology - Burning Rock's MRD assay, brPROPHET™, demonstrated a median lead time of 299 days to radiological recurrence in NSCLC[43] - In a study, brPROPHET™ detected preoperative ctDNA in 97% (113/117) of colorectal cancer patients[136,141] - For early cancer detection, the THUNDER study (N=2,385) completed with 98.9% specificity and 69.1% sensitivity, top-2 predicted origin accuracy of 91.7% (independent validation cohort)[67,79] - The PROMISE study demonstrated 83.7% sensitivity and 98.3% specificity for 9 cancers[103] Therapy Selection - Burning Rock's liquid biopsy product, Lung Plasma v4 (BRP2), demonstrated globally competitive performance in an analytical validation study[150,160]

GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Con ...

GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and th ...

GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2024 before the U.S. market opens on May 29, 2024. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) o ...

GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2024 before the U.S. market opens on May 29, 2024. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong ...

GUANGZHOU, China, May 14, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that, as previously announced on April 26, 2024, the ratio change of its American depositary shares (the "ADSs") to Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS representing ten (10) Class A o ...

Table of Contents Title of each classTrading SymbolName of each exchange on which registered American depositary shares, each representing one Class A ordinary share BNR The Nasdaq Stock Market LLC (The Nasdaq Global Market) Class A ordinary share, par value US$0.0002 per share* The Nasdaq Stock Market LLC (The Nasdaq Global Market) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES ACT OF 1 ...

GUANGZHOU, China, April 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 29, 2024 it filed its Annual Report on Form 20-F for the year ended December 31, 2023 (the "Form 20-F") with the U.S. Securities and Exchange Commission ("SEC"). The Form 20-F is available for viewing on the SEC website at www.sec.gov and also ...